Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc; Celgene Corporation; Daiichi Sankyo, Inc; Eisai, Inc; Exelixis, Inc.; Ignyta; Incyte Corporation; Ipsen Biopharmaceuticals, Inc; Lilly; Novartis Pharmaceuticals Corporation; Novocure; Pharmacyclics LLC, an AbbVie Company; Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC; Pfizer; Taiho Oncology; and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette Series


Release Date: January 31, 2018
Expiration Date: January 31, 2019
Media: Internet - based

 

Activity Overview

Providing state-of-the-art cancer care through diagnostic, therapeutic, and supportive strategies is dependent upon incorporating the latest clinical advancements and data into practice. In solid tumors and hematologic malignancies alike—and across all cancer types—novel approaches in testing, systemic therapy, targeted and immunotherapies, and combination strategies continue to drive improvements in patient outcomes. Now in its 35th year, the Chemotherapy Foundation Symposium (CFS®) brings together more than 2000 healthcare professionals, including oncologists, hematologists, radiologists, immunologists, pharmacists, nurse practitioners, physician assistants, and patient advocates, and strives to deliver the latest answers to your clinical challenges. Our internationally renowned faculty will provide expert analysis on the most recent developments in cancer therapies, synthesizing scores of data to provide attendees with the critical distilled information they need. This preeminent online activity provides an unparalleled opportunity to learn new methods of personalizing care for your patients with cancer. Together, we will Innovate Cancer Therapy for Tomorrow®.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc; Celgene Corporation; Daiichi Sankyo, Inc; Eisai, Inc; Exelixis, Inc.; Ignyta; Incyte Corporation; Ipsen Biopharmaceuticals, Inc; Lilly; Novartis Pharmaceuticals Corporation; Novocure; Pharmacyclics LLC, an AbbVie Company; Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC; Pfizer; Taiho Oncology; and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

 

CME/CE Activity Table of Contents

  • Module 1: Therapeutic Decision Making for Advanced Lung Adenocarcinoma
    Benjamin Levy, MD
  • Module 2: Therapy for Newly Diagnosed Multiple Myeloma
    Ajai Chari, MD
  • Module 3: Therapy for Relapsed Multiple Myeloma
    Ajai Chari, MD
  • Module 4: Management of Metastatic Prostate Cancer
    William Oh, MD
  • Module 5: Management of Hormone Receptor‒Positive, HER2-Negative Breast Cancer
    Adam Brufsky, MD, PhD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Determine the most appropriate testing strategies to stratify risk and inform clinical decision making in the management of cancer
  • Describe important clinical trial results that inform treatment practices and are altering care paradigms for patients with hematologic malignancies and solid tumors
  • Identify immunotherapeutic, chemotherapeutic, and targeted approaches demonstrated by recent evidence to optimize clinical outcomes
  • Delineate methods that multidisciplinary teams can proactively apply to prevent and mitigate the impact of treatment-related toxicities findings in the context of evolving treatment pathways to improve care for patients with cancer
  • Examine practice-changing evidence, and apply these findings in the context of evolving treatment paradigms to optimize the care of patients with cancer

Faculty, Staff, and Planners' Disclosures

Faculty

Benjamin Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
 

Disclosure: Consultant: Genentech, Eli Lilly, AstraZeneca, Celgene, Bristol-Myers Squibb, Merck

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/ Oncology
Co-Director, Comprehensive Breast Cancer Center
Associate Director, Clinical Investigation
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure: Consultant: Novartis, Roche, Eisai, Celgene, Lilly, Pfizer, Agendia, Genomic Health, NanoString Technologies, Biotheranostics

Ajai Chari, MD
Associate Professor
Medicine, Hematology and Medical Oncology
The Mount Sinai Hospital
New York, NY
 

Disclosure: Grant/Research Support: Array Biopharma, Celgene, Novartis, Millennium/Takeda, Amgen, Janssen Oncology, Pharmacyclics; Consultant: Array BioPharma, Celgene, Novartis, Millennium/Takeda, Amgen, Janssen Oncology, Bristol-Myers Squibb

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Deputy Director, Tisch Cancer Institute
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure: Consultant: AstraZeneca, Bayer, Churchill Pharmaceuticals, Dendreon, Janssen, Sanofi; Shareholder: Checkpoint Therapeutics

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.




PER Pulse™ Recap (1 of 3)

35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the Symposium who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Therapeutic Decision Making for Advanced Lung Adenocarcinoma
    Benjamin Levy, MD
  • Therapy for Newly Diagnosed Multiple Myeloma
    Ajai Chari, MD
  • Therapy for Relapsed Multiple Myeloma
    Ajai Chari, MD
  • Management of Metastatic Prostate Cancer
    William Oh, MD
  • Management of Hormone Receptor‒Positive, HER2-Negative Breast Cancer
    Adam Brufsky, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Levy’s answers to questions about frontline treatment for advanced lung cancer. During his interview, Dr. Levy:

  • Discusses his approach for a 63-year-old male former smoker (ECOG PS 1) who was employed full time when he presented with a large adrenal mass 2 years post-resection of a 1.1-cm right upper lobe adenocarcinoma. Biopsy tissue analysis: TTF-1-positive; EGFR-, ALK-, ROS1-, and BRAF V600E-negative; PD-L1 staining (22C3) is 20%. PET-CT: large PET-avid right adrenal lesion and 2 small but hypermetabolic lung nodules. Negative for brain involvement. Brain magnetic resonance imaging was negative.
  • Shares his perspective on a variety of issues, including investigations of immunotherapy in curative settings and evidence for activity of immunotherapy in other thoracic malignancies (eg, small cell lung cancer, mesothelioma).
  • Discusses his approach, and related issues, regarding additional cases:
    • A 67-year-old female never-smoker who presented with de novo metastatic TTF-1+, non-small cell lung cancer (NSCLC) with an EGFR exon 19 deletion and PD-L1 expression (22C3) of 70%
    • A 52-year-old male with a 25-pack-year history with ALK rearranged NSCLC

Resources

PER Pulse™ Recaps for 35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspectives on case management decisions is provided in these summaries.




PER Pulse™ Recap (2 of 3)

35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the Symposium who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Therapeutic Decision Making for Advanced Lung Adenocarcinoma
    Benjamin Levy, MD
  • Therapy for Newly Diagnosed Multiple Myeloma
    Ajai Chari, MD
  • Therapy for Relapsed Multiple Myeloma
    Ajai Chari, MD
  • Management of Metastatic Prostate Cancer
    William Oh, MD
  • Management of Hormone Receptor‒Positive, HER2-Negative Breast Cancer
    Adam Brufsky, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Chari’s answers to questions about frontline therapy for newly diagnosed multiple myeloma (MM). During his interview, Dr. Chari:

  • Discusses his initial approach for a 53-year-old male who was diagnosed with MM after complaining of back pain, later shown to stem from a compression fracture involving T12 vertebrae and multiple lytic lesions. Additional workup was significant for a normal serum creatinine and calcium, and mild anemia with hemoglobin of 12.2 g/dL. Serum B2 microglobulin was 6.5 mg/dL and serum albumin was 4.1 g/dL. Bone marrow showed 40% plasma cells, and plasma cell fluorescence in situ hybridization showed the t(4;14) translocation with deletion 17p.
  • Shares his approach toward next-line therapy when this patient achieved a very good partial response after 4 cycles of initial therapy.
  • Reviews data regarding doublet versus triplet induction regimens and the role for transplantation in the era of triplet therapy for newly diagnosed MM.

 




PER Pulse™ Recap (3 of 3)

35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the Symposium who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Therapeutic Decision Making for Advanced Lung Adenocarcinoma
    Benjamin Levy, MD
  • Therapy for Newly Diagnosed Multiple Myeloma
    Ajai Chari, MD
  • Therapy for Relapsed Multiple Myeloma
    Ajai Chari, MD
  • Management of Metastatic Prostate Cancer
    William Oh, MD
  • Management of Hormone Receptor‒Positive, HER2-Negative Breast Cancer
    Adam Brufsky, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Brufsky’s answers to questions about therapy for advanced breast cancer. During his interview, Dr. Brufsky:

 

  • Discusses his approach toward bone supportive therapy for a thin, 43-year-old female with a history of smoking (she quit 10 years ago), who had a recent left modified radical mastectomy for a 3-cm infiltrating ductal carcinoma, estrogen receptor (ER) 80%, progesterone receptor 60%, HER2-negative (ratio 1.3), grade 2, Ki67 10%. Two of 13 lymph nodes are positive for metastatic adenocarcinoma. She is low risk by the 70-gene assay. A recent lumbar spine bone mineral density test shows a T score of -1.9.
  • Shares his perspectives on available assays to assess patient risk for breast cancer recurrence and implementation of the 8th edition of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines and the American Joint Committee on Cancer Staging System for Breast Cancer.
  • Reviews therapeutic options for a 54-year-old postmenopausal female who was initially diagnosed with stage 3, node-positive, ER+, HER2-negative breast cancer (for which she received adjuvant chemotherapy and was receiving letrozole), and who has developed metastatic disease to the bone and liver.







Become a Member

Forgot Password?
Filter By